For instance, ADJUVANT study is designed to assess the efficacy and safety of crizotinib as adjuvant therapy in ALK-positive NSCLC patients at stage IB, II, or IIIA after resection surgery, the trial is estimated to complete in 2023 (NCT01283516). Here, ALK is linked to non-small cell lung carcinoma.